Biomaterials Advances is a premier journal published by Elsevier, dedicated to the rapidly evolving field of biomaterials. Established in the United Kingdom, this open-access journal aims to disseminate high-quality, peer-reviewed research that explores innovative biomaterial designs and their applications in bioengineering and biomedical engineering. With an impressive 2023 impact factor reflected in its Q1 rankings across multiple categories—including Bioengineering, Biomaterials, and Biomedical Engineering—Biomaterials Advances stands out as a critical platform for scholars and practitioners faced with advancing technologies and methodologies in the realm of materials science. Covering a broad range of topics, from biocompatibility to tissue engineering, this journal provides an inclusive forum for researchers seeking to contribute to the field. Its Scopus rankings further affirm its position as a leading resource, with notable standings in Biomedical Engineering (Rank #13), Biomaterials (Rank #8), and Bioengineering (Rank #11), all within the top percentiles. Researchers and students alike are encouraged to contribute and engage with the latest findings and innovations in biomaterials through this valuable publication.

Regenerative Engineering and Translational Medicine is an esteemed academic journal published by Springer Heidelberg, focusing on the interdisciplinary fields of biomaterials, biomedical engineering, and cell biology. With an ISSN of 2364-4133 and an E-ISSN of 2364-4141, the journal has carved a niche for itself since its inception in 2015, showcasing cutting-edge research that bridges the gap between scientific findings and practical applications in regenerative medicine. As a recognized platform in its field, it is currently positioned within Q3 quartiles in biomaterials, biomedical engineering, and medicine (miscellaneous), with a Scopus ranking that reflects its growing influence among peers. The journal aims to disseminate high-quality, peer-reviewed articles that highlight advancements in regenerative engineering, further advancing both theoretical and applied research. Scholars and practitioners seeking to stay at the forefront of the ever-evolving landscape of regenerative health solutions will find invaluable insights and innovations within these pages. Join a community of leading thinkers and explore the journal's comprehensive research contributions, which are crucial for fostering partnerships between academia and industry in the quest for transformative medical solutions.

Artificial Cells Nanomedicine and Biotechnology is a prestigious peer-reviewed journal published by TAYLOR & FRANCIS LTD, specializing in the rapidly evolving fields of biomedical engineering, biotechnology, and nanomedicine. Established in 2013 and operating under an open-access model since 2019, the journal aims to bridge the gap between fundamental science and real-world medical applications, showcasing cutting-edge research that advances our understanding of artificial cells and their biotechnological applications. With an impressive impact factor and ranking in the Q2 quartile across various categories, including Biomedical Engineering, Medicine, and Pharmaceutical Sciences, the journal is a leading platform for innovative studies that contribute significantly to the realm of healthcare and therapeutic development. Researchers, professionals, and students alike will find invaluable insights and advancements within its pages, positioning it as a vital resource for those dedicated to pushing the boundaries of science and improving patient outcomes.

Asian Journal of Pharmaceutical Sciences is a prestigious open-access journal published by Shenyang Pharmaceutical University, dedicated to advancing research and developments in the field of pharmaceutical sciences. Since its inception in 2009, the journal has successfully converged a wealth of knowledge and innovation, demonstrating an impressive track record with its open access model adopted in 2013, ensuring global dissemination of crucial research findings. With an outstanding impact factor and consistently ranked in the Q1 category for both Pharmaceutical Science and Pharmacology in 2023, it ranks among the top journals in its field, as evidenced by its impressive Scopus rankings—4th out of 183 in Pharmaceutical Science and 10th out of 313 in Pharmacology, showcasing its high relevance and credibility (98th and 96th percentiles respectively). Researchers, professionals, and students can access a diverse array of articles that encompass groundbreaking studies, reviews, and reports, solidifying the journal's position as a vital resource for anyone engaged in pharmaceutical research. With its commitment to quality and accessibility, Asian Journal of Pharmaceutical Sciences plays an essential role in fostering innovation and collaboration within the global scientific community.

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.

Advanced Pharmaceutical Bulletin, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, serves as a pivotal platform for disseminating groundbreaking research in the field of pharmaceutical sciences. Since its inception in 2011, this open-access journal has dedicated itself to advancing knowledge in pharmacology, toxicology, and pharmaceutics, boasting an impressive Q1 ranking in miscellaneous categories and Q2 in pharmaceutical science as of 2023. The journal is noted for its rigorous peer-review process, ensuring that published work meets the highest standards of scientific inquiry. With notable rankings, including 7th out of 80 in general pharmacology and toxicology, it sits in the 91st percentile, highlighting its significance in the research community. Researchers and practitioners alike can access cutting-edge findings and innovative methodologies, promoting collaboration and knowledge within the scientific community. Based in Tabriz, Iran, the journal remains committed to fostering research excellence, making it an invaluable resource for scholars and professionals eager to contribute to the dynamic field of pharmaceuticals.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

APL Bioengineering is a premier open-access journal published by AIP Publishing, dedicated to advancing the field of bioengineering and its interdisciplinary applications. Established in 2017, this journal serves as a vital platform for researchers, professionals, and students interested in the critical intersections of bioengineering, biomaterials, biomedical engineering, and biophysics. With an impressive impact factor and consistent rankings in the Q1 category across multiple domains, including biochemistry and materials science, APL Bioengineering has positioned itself among the top journals in its field. The journal aims to publish innovative original research, comprehensive reviews, and insightful case studies that further the understanding and application of bioengineering principles. Since its inception, APL Bioengineering has fostered a community of thought leaders, providing open access to ensure broad dissemination of knowledge and advancements that underpin the future of biomedical innovation.

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

Nanomedicine, published by Future Medicine Ltd, is a premier academic journal dedicated to the rapidly evolving field of nanotechnology in medicine. With an emphasis on innovative research and applications, this journal encompasses a broad spectrum of topics including bioengineering, biomedical engineering, and nanoscience, among others. Featuring an impressive Q1 ranking in Development and multiple Q2 rankings across significant categories, it serves as a pivotal resource for researchers and professionals aiming to stay at the forefront of advancements in these disciplines. While the journal is not open access, it is accessible through various institutional subscriptions, ensuring wide dissemination of cutting-edge findings. Notably, it has achieved substantial impact within the scientific community, indicated by its high rankings in Scopus and overall commitment to enhancing the understanding and application of nanomedicine. This journal is a vital conduit for fostering collaborations and innovations that transcend traditional medical paradigms.